Pulmicort, Budesonide News

SAN DIEGO A pharmaceutical company focused on drugs for children has filed a lawsuit against Anglo-Swedish drug maker AstraZeneca.

Verus Pharmaceuticals, Inc. , a specialty pharmaceutical company, announced today that it has filed a lawsuit against AstraZeneca AB and Tika Lakemedel AB in the Supreme Court of the State of New York, in which it is seeking $1.3 billion on claims of fraud, breach of contract, and conversion.

Main Category: COPD Also Included In: Respiratory / Asthma Article Date: 27 May 2009 - 5:00 PDT Preliminary results from a double-blind, randomised, multicentre trial among 660 patients with chronic obstructive pulmonary disease show that budesonide/formoterol plus tiotropium significantly improves disease control and patients' quality of life.1,2 ...

Data presented at this year's American Thoracic Society congress, demonstrated that SYMBICORT added to SpirivaTM provided greater clinical improvements than tiotropium alone over a 12-week treatment period.1,2 Results of the CLIMB study showed that the occurrence of severe exacerbations was reduced by as much as 62 percent in patients where ...

Asthma is a fairly common health problem for pregnant women, including some women who have never had it before.

On May 20, 2009, the US District Court for the District of New Jersey granted the request of AstraZeneca for an injunction barring Apotex from launching a generic version of AstraZeneca's Pulmicort Respules in the US.

MAP Pharmaceuticals, Inc. today announced that the company will present at the Deutsche BankSecurities 34th Annual Health Care Conference on Tuesday, May 19, 2009 at 2:35 p.m. in Boston, MA.

AstraZeneca Plc , the U.K.a s second- biggest drugmaker, won a bid to temporarily block Apotex Inc.

On 16 April 2009, the US District Court for the District of New Jersey granted AstraZeneca's request for a temporary restraining order, barring Apotex from launching a generic version of AstraZeneca's PULMICORT RESPULES until further order of the court.

Traditionally inhaled treatment for asthma has been considered as preventer and reliever therapy.

People suffering from chronic asthma might have a new treatment option that allows them to manage their condition with a single prescribed inhaler that contains two medicines, according to a new review.

Main Category: Respiratory / Asthma Also Included In: Pharma Industry / Biotech Industry AstraZeneca announced the company has received a Complete Response Letter from the US Food and Drug Administration for SYMBICORT pressurized metered dose inhaler for the long-term maintenance treatment of asthma in paediatric patients ages 6-11 years.

Winnipeg police have issued a warning about some prescription drugs taken in a purse snatching Saturday night from a female leaving a business in the 900 block of Jefferson Avenue.

Drugmaker AstraZeneca said Tuesday that it has filed a lawsuit in the U.S. District Court for the District of New Jersey against Apotex seeking a declaration of patent infringement.

The use of Symbicort for the long-term maintenance treatment of asthma is already approved for patients aged 12 and over in the United States and the company has applied to sell it for the same purpose for children aged six to 11.

Results of a late-stage trial of MAP Pharmaceuticals Inc's inhaled migraine drug will represent a critical moment for the company given the recent failure of its other key drug to treat asthma in children.

EWING, N.J., March 13, 2009 /PRNewswire-FirstCall/ DOR BioPharma, Inc. announced today that it has appointed Brian L. Hamilton, MD, PhD, as Senior Vice President and Chief Medical Officer.

AstraZeneca has received approval to update the patient instructions on its Pulmicort Flexhaler , thanks to nurses' reports on patient confusion with the device's dose counter.

The FDA approval is based on results from two pivotal clinical trials, SHINE and SUN , which found SYMBICORT significantly improved lung function within five minutes of the first dose and sustained that lung ...

MAP Pharmaceuticals Inc. said that its potential treatment for asthma in children did not improve symptoms any better than placebo in a Phase III study of unit dose budesonide , leaving the program in limbo for ...